drugset
drugset / Trial / NCT03256968

PTC Study to Evaluate Ataluren in Combination With Ivacaftor

NCT03256968 ↗

Phase 4 Completed 1 enrolled University of Alabama at Birmingham
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to explore the combination of ataluren and ivacaftor as a treatment for patients with nonsense mutation cystic fibrosis

Timeline

Start
2017-01-27
Primary completion
2018-12-01
Completion
2018-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ataluren Small molecule — —

Indications

cystic fibrosis